• MicroRNAs as functional state biomarkers of hepatocytes among infants with prolonged conjugational jaundice.
To content

MicroRNAs as functional state biomarkers of hepatocytes among infants with prolonged conjugational jaundice.

SOVREMENNAYA PEDIATRIYA.2014.3(59):116-120; doi 10.15574/SP.2014.59.116

 

MicroRNAs as functional state biomarkers of hepatocytes among infants with prolonged conjugational jaundice.

 

Lenchenko A. V., Chernega N. F., Shadrin O. G., Dosenko V. E. 
Institute of Pediatrics, Obstetrics and Gynecology of NAMS of Ukraine, Kiev

Children`s Municipal Clinical Hospital, Uzhgorod, Ukraine

Bogomolets Institute of Physiology, Kiev, Ukraine

 

Purpose: to determine the expression levels of miRNA-21-3p and miRNA-885-5p in the serum of infants with prolonged conjugation jaundice (PCJ).

 

Patients and methods: blood samples of 22 infants with PCJ and 28 healthy infants (control group) were tested. Expressions of miRNA-217-3p and miRNA-885-5p according to TaqMan techniques in the blood serum of newborns with PCJ and control groups were determined.

 

Results: miRNA profile studies revealed significantly lower expression levels of miR-21-3p and miR-885-5p among children with PCJ comparing with healthy children that indicates the functional state intensity of the hepatobiliary system, and decrease of hepatocytes functional activity.

 

Conclusions: increased susceptibility of hepatocytes to the activity of various negative factors among children with PCJ indicates the need to prescribe the complex treatment of this pathology with hepatoprotective drugs for the liver parenchyma retention at rest condition.

 

Key words: infants, prolonged conjugation jaundice, hepatocytes, miRNA-21-3p, miRNA-885-5p.

 

REFERENCES

1. Афонин А, Шокарев А, Левкович А. 2010. Комплексная терапия гипербилирубинемии новорожденных с перинатальным поражением центральной нервной системы. Врач. 8: 58—59.

2. Кайдашев ИП. 2008. Перспективы изучения и применения микроРНК в иммунологии и аллергологии. Клин иммунол. Аллергол. Инфектол. 7.

3. МикроРНК (материал из Википедии). http://ru.wikipedia.org.

4. Шадрін ОГ, Марушко ТЛ, Басараба НМ, Шадрін ВО. 2009. Питання оптимізації терапії кон'югаційної жовтяниці новонароджених. Перинатол і педіатрія. 4(40): 51—53.

5. Про затвердження клінічного протоколу надання неонатальної допомоги дітям «Жовтяниці новонароджених». Наказ МОЗ України № 255 від 27.04.2006. К. 2006: 38.

6. РНК-інтерференція (матеріал з Вікіпедії). http://uk.wikipedia.org/wiki.

7. Cheng Y, Tan N, Yang J, Liu X et al. 2010. A translational study of circulating cell-free microRNAs-1 in acute myocardial infarction. Clin Sci. 119: 87—95.

8. Yamada H et al. 2013. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta. 424: 99—103.

9. Chen X, Ba Y, Ma L et al. 2008. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18: 997—1006.

10. Marquez RT, Bandyopadhyay S, Wendlandt EB et al. 2010. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest. 90: 1727—1736.

11. Winther TN, Bang-Berthelsen CH, Heiberg IL et al. 2013. Differential Plasma MicroRNA Profiles in HBeAg Positive and HBeAg Negative Children with Chronic Hepatitis B. PLOS ONE. 8; Issue 3: 58236.

12. Dimmeler S, Nigotera P. 2013. MicroRNA in age-related diseases. EMBO Molecular Medicine. 5; Issue 2: 180—190.

13. Schug J, McKenna L, Walton G et al. 2013. Dynamic recruitment of microRNAs to their mRNA targets in the regenerating liver. BMC Genomics. 14: 264. http://www.biomedcentral.com/1471—2164/14/264.

14. Castro RE, Ferreira DM, Zhang X et al. 2010. Identification of microRNAs during rat liver regeneration after partial hepatectomy and modulation by ursodeoxycholic acid. Am J Physiol Gastrointest Liver Physiol. 299(4): 887—897.

15. Kosaka N, Izumi H, Sekine K, Ochiya T. 2010. MicroRNA as a new immune-regulatory agent in breast milk. Silence. 1: 7. http://www.silencejournal.com/content/1/1/7.

16. Marquez RT, Wendlandt E, Galle CS et al. 2010. MicroRNA-21 is upregulated during the proliferative phase of liver regeneration, targets Pellino-1, and inhibits NF-kappaB signaling. Am J Physiol Gastrointest Liver Physiol. 298: 535—541.

17. Hu J, Wang Z, Tan CJ et al. 2013. Plasma microRNA, a potential biomarker for acute rejection after liver transplantation. Transplantation. 27;95(8): 991—9. http://dx.doi.org/10.1097/tp.0b013e31828618d8

18. Gui J, Tian Y, Wen X, Zhang W et al. 2011. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clinical Science. 120: 183-193.

19. Resnick KE, Alder H, Hagan JP et al. 2009. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 112: 55—59.

20. Ting-Fang Lo, Wei-Chung Tsai. 2013. MicroRNA-21-3p, a Berberine-Induced miRNA, Directly Down-Regulates Human Methionine Adenosyltransferases 2A and 2B and Inhibits Hepatoma Cell Growth. PLOS ONE. http://www.plosone.org.

21. Xia H, Ooi LL, Hui KM. 2013. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology. 58(2): 629—41. http://dx.doi.org/10.1002/hep.26369; PMid:23471579